AA Parulkar, ML Pendergrass, R Granda- … - Ann Intern Med, 2001 - Am Coll Physicians The thiazolidinediones are a new class of compounds for treat- ment of type 2
diabetes. Troglitazone became available in the United States in 1997 but was
withdrawn from the market in March 2000 because it caused severe ... Cited by 416 - Related articles - All 4 versions
P Suwattee, C DeSouza, S Asnani, L Gilling, … - The Endocrinologist, 2002 - journals.lww.com CHIEF EDITOR'S NOTE: This article is the 10th of 36 that will be published in
2002 for which a total of up to 36 Category 1 CME credits can be earned.
Instructions for how credits can be earned appear after the Table of Contents. Cited by 7 - Related articles - BL Direct
- ►endojournals.org [PDF] H Koshiyama, D Shimono, N Kuwamura, J … - Journal of Clinical Endocrinology & Metabolism, 2001 - Endocrine Soc 3454 RAPID COMMUNICATIONS JCE & M • 2001 Vol. 86 • No. 7 Multiple regression
analysis indicated that there was no statistically significant relation between
a decrease in IMT and those in HbAlc. DISCUSSION The present study ... Cited by 370 - Related articles - BL Direct - All 5 versions
- ►adisonline.com [PDF] L Gilling, P Suwattee, C DeSouza, S Asnani, … - American Journal of Cardiovascular Drugs, 2002 - ingentaconnect.com Abstract Rosiglitazone and pioglitazone are medications from the
thiazolidinedione class of compounds currently available for the treatment of
type 2 diabetes mellitus. Traditionally used to enhance insulin sensitivity ... Cited by 25 - Related articles - All 3 versions
FA Masoudi, Y Wang, SE Inzucchi, JF Setaro … - Jama, 2003 - Am Med Assoc Context According to package inserts, metformin is contraindicated in diabetic
patients receiving drug treatment for heart failure therapy, and
thiazolidinediones are not recommended in diabetic patients with symptoms ... Cited by 107 - Related articles - BL Direct - All 8 versions
- ►ahajournals.org SM Haffner, AS Greenberg, WM Weston, H … - Circulation, 2002 - Am Heart Assoc Background— Markers of systemic inflammation (eg, C-reactive protein [CRP] and
interleukin-6 [IL-6]) have been proposed to be "nontraditional" risk factors for
cardiovascular disease in patients with type 2 diabetes mellitus. Matrix ... Cited by 822 - Related articles - BL Direct - All 9 versions
- ►zhaoys.com [PDF] V Fonseca, J Rosenstock, R Patwardhan, A … - Jama, 2000 - Am Med Assoc Context Most antidiabetic agents target only 1 of several underlying causes of
diabetes. The complementary actions of the antidiabetic agents metformin
hydrochloride and rosiglitazone maleate may maintain optimal glycemic ... Cited by 518 - Related articles - BL Direct - All 8 versions
MA Khan, JV St Peter, JL Xue - Diabetes Care, 2002 - Am Diabetes Assoc RESULTS—A total of 127 patients completed follow-up: 67 individuals in the PIO
group (32 women, 35 men) and 60 individuals in the ROSI group (33 women, 27
men). There were no significant differences in gender mix, age, weight, ... Cited by 230 - Related articles - BL Direct - All 6 versions
BP Gouda, S Asnani, VA Fonseca - Comprehensive therapy, 2002 - Springer The thiazolidinediones (TZDs) are “insulin sensitiz- ers” developed for
treatment of Type 2 diabetes mellitus. The efficacy of these drugs in lowering
plasma glucose is well-established. 1-4 They decrease insulin resistance at ... Cited by 3 - Related articles - BL Direct - All 3 versions
S Asnani, P Theuma, VA Fonseca - Metabolic Syndrome and Related Disorders, 2003 - liebertonline.com Peroxisome proliferator–activated receptors (PPARs) are members of the nuclear
receptor su- perfamily comprising four subtypes designated PPARa, PPARg1,
PPARg2, and PPARd. These are transcription factors that regulate gene ... Cited by 3 - Related articles - BL Direct - All 3 versions
